European Union - English - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - tovanor breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations

Canada - English - Health Canada

salix pharmaceuticals inc - rifaximin - tablet - 550mg - rifaximin 550mg - rifamycins

United States - English - NLM (National Library of Medicine)

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - losartan potassium - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - colistimethate sodium - powder for solution for injection - 1000000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - caffeine citrate - solution for infusion - 20mg/1ml

European Union - English - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark arzneimittel gmbh - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - injection - see ingredients - each 1,0 ml solution contains phenylephrine hydrochloride 10,0 mg